Project Grant R21AR084251
Award Date
9/6/24
Completion Date
8/31/26
Dollars Obligated
$100K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $110,959 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the mechanisms driving the transition of lipofibroblasts to myofibroblasts in systemic sclerosis, a rare autoimmune fibrosing disease with high mortality. The research aims to define the role of the genes PER3 and CD36 in regulating the lipofibroblast to myofibroblast transition, which is a key driver...
This $1,644,550 Cooperative Agreement award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to understand how interactions between epithelial, mesenchymal, and matrix compartments drive progressive fibrosis in interstitial lung diseases (ILD). The award will fund a multidisciplinary team from the University of California, Los Angeles (UCLA) to use spatial transcriptomics, single-cell secretion analysis, and regional proteomics...
This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,061,189 to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The key objectives are to study epithelial cell regulation of fibrosis and its interaction with myeloid cells, uncover mechanisms for impaired innate immunity against gram-positive infections in fibrosis, test delivery of targeted therapeutics...
This Project Grant award of $539,218.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research to develop and validate a prediction model for progression-free survival in patients with myositis-associated interstitial lung disease (ILD). The research aims to identify novel biomarkers and subphenotypes to better understand the clinical and biological heterogeneity of myositis-ILD. The award was granted to The Trustees of the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,659,996 to the University of Southern California (USC) from April 1, 2025 to January 31, 2029. The funding supports research to investigate the role of the protein PDLIM2 in regulating alveolar macrophage function, which is critical for lung innate immunity, inflammation, and respiratory diseases. The research aims to elucidate the...
This $1,546,880 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the regulatory mechanisms governing myofibroblast differentiation in idiopathic pulmonary fibrosis (IPF). The primary objectives are to: 1) determine the "regulatory architecture" of open chromatin in myofibroblasts in IPF, 2) examine how expression levels of E-box transcription factors...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $145,642 to Georgia Tech Research Corporation to engineer 3D pulmonary microtissue models to explore the role of fibroblast senescence in the development and progression of idiopathic pulmonary fibrosis (IPF). The project aims to: 1) develop an in vitro pulmonary microtissue model to assess differences in contractility, stiffness, cell...
This federal Project Grant award, valued at $715,957 and awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA Program 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research, supports research to elucidate the molecular mechanisms by which interferon cytokines promote the differentiation and expansion of T peripheral helper (Tph) cells in systemic lupus erythematosus (SLE) patients. The award, with a project period from March 2025 to...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $2,241,717 to the University of Pittsburgh to conduct research on the role of plasma cells in chronic rejection after lung transplantation. The key goals are to: 1) Provide a comprehensive map of B and plasma cell gene expression, population heterogeneity, and temporal dynamics in chronically rejected lungs after transplantation; and 2) Mechanistically interrogate...